FGFR3 Antibody
| Code | Size | Price |
|---|
| PSI-7425-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7425-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
FGFR3 Antibody: ACH, CEK2, JTK4, CD333, HSFGFR3EX, Fibroblast growth factor receptor 3, FGFR-3
Application Note:
FGF3 antibody can be used for detection of FGFR3 by Western blot at 1 - 2 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Background:
FGFR3 Antibody: FGFR3 is a tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis (1). It is required for normal skeleton development and promotes apoptosis in chondrocytes and cancer cell proliferation. FGFR3 protein contains three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain (1,2). It is alternatively spliced to produce three isoforms that are expressed in brain, kidney and testis. Defects in FGFR3 are associated with several diseases, including achondroplasia and hypochondroplasia (3,4). Mutations in FGFR3 are also a cause of some bladder and cervical cancers (5).
Background References:
- Keegan K, Johnson DE, and Williams LT. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc. Natl. Acad. Sci. USA 1991; 88:1095-9.
- Turner N and Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010; 10:116-29.
- Superti-Furga A, Eich G, Bucher HU, et al. A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur. J. Pediatr. 1995; 154:215-9.
- Bellus GA, McIntosh I, Smith EA, et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat. Genet. 1995; 10:357-9.
Buffer:
FGFR3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Chicken: (95%)
Immunogen:
FGFR3 antibody was raised against a 19 amino acid peptide near the carboxy terminus of human FGFR3.
The immunogen is located within amino acids 630 - 680 of FGFR3.
The immunogen is located within amino acids 630 - 680 of FGFR3.
Molecular Weight Explanation:
Probable post-translational modification
NCBI Gene ID #:
2261
NCBI Official Name:
fibroblast growth factor receptor 3
NCBI Official Symbol:
FGFR3
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 89 kDa
Observed: 9+2, 98 kDa
Observed: 9+2, 98 kDa
Protein Accession #:
NP_001156685
Protein GI Number:
254028242
Purification:
FGFR3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Stem Cell
SPECIFICITY:
FGFR3 antibody is human, mouse and rat reactive. At least three isoforms of FGFR3 are known to exist; this antibody will detect all three.
Swissprot #:
P22607
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | FGFR3 Peptide | PSI-7425P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|